Key result
Nanoparticle-facilitated siRNA targeting CCR2 improved ejection fraction on day 21 after myocardial infarction from 29% to 35% (P<0.05) in apoE(-/-) mice.
Why the study?
Does nanoparticle-facilitated silencing of CCR2 reduce infarct inflammation and improve left ventricular remodeling in apoE(-/-) mice after MI?
Does nanoparticle-facilitated silencing of CCR2 reduce infarct inflammation and improve left ventricular remodeling in apoE(-/-) mice after MI?
Absolute Event Rate: 35% vs 29%
p-value: p=<0.05
Nanoparticle-facilitated CCR2 silencing reduces infarct inflammation and improves post-MI left ventricular ejection fraction in a mouse model.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications; leaves open translation of CCR2-targeted siRNA to human post-MI remodeling.
Majmudar et al. (2013) studied Myocardial infarction. Nanoparticle-facilitated siRNA targeting CCR2 was evaluated on Ejection fraction on day 21 after myocardial infarction (p=<0.05). Nanoparticle-facilitated siRNA targeting CCR2 improved ejection fraction on day 21 after myocardial infarction from 29% to 35% (P<0.05) in apoE(-/-) mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: